Evidence map›Paper›PMID 38590856›Full record

ArticleHeliyon2024

Design, synthesis and in silico molecular docking evaluation of novel 1,2,3-triazole derivatives as potent antimicrobial agents.

Sudhakar Reddy Baddam, Mahesh Kumar Avula, Raghunadh Akula, Venkateswara Rao Battula, Sudhakar Kalagara, Ravinder Buchikonda, Srinivas Ganta, Srinivasadesikan Venkatesan, Tejeswara Rao Allaka

Open access · goldAbstract read
In one paragraph

Article in Heliyon, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
3.5field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 14 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 6 institutions in 2 countries.

Sudhakar Reddy BaddamUniversity of Massachusetts Chan Medical School, RNA Therapeutic Institute, Worcester, MA, 01655, United States.
Mahesh Kumar AvulaTechnology Development Center, Custom Pharmaceutical Services, Dr. Reddy's Laboratories Pvt. Ltd., Hyderabad, Telangana, 500049, India.
Raghunadh AkulaTechnology Development Center, Custom Pharmaceutical Services, Dr. Reddy's Laboratories Pvt. Ltd., Hyderabad, Telangana, 500049, India.
Venkateswara Rao BattulaDepartment of Chemistry, AU College of Engineering (A), Andhra University, Visakhapatnam, Andhra Pradesh, 530003, India.
Sudhakar KalagaraDepartment of Chemistry and Biochemistry, University of the Texas at El Paso, El Paso, TX, 79968, United States.
Ravinder BuchikondaTechnology Development Center, Custom Pharmaceutical Services, Dr. Reddy's Laboratories Pvt. Ltd., Hyderabad, Telangana, 500049, India.
Srinivas GantaScieGen Pharmaceutical Inc., Hauppauge, NY, 11788, United States.
Srinivasadesikan VenkatesanDepartment of Chemistry, School of Applied Science and Humanities, VIGNAN's Foundation for Science, Technology and Research, Vadlamudi, Andhra Pradesh, 522213, India.
Tejeswara Rao AllakaCentre for Chemical Sciences and Technology, Institute of Science and Technology, Jawaharlal Nehru Technological University Hyderabad, Kukatpally, Hyderabad, Telangana, 500085, India.
Andhra University · INDr. Reddy's Laboratories (India) · INJawaharlal Nehru Technological University, Hyderabad · INThe University of Texas at El Paso · USUniversity of Massachusetts Chan Medical School · USVignan's Foundation for Science, Technology & Research · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chalcone and triazole scaffolds have demonstrated a crucial role in the advancement of science and technology. Due to their significance, research has proceeded on the design and development of novel benzooxepine connected to 1,2,3-triazolyl chalcone structures. The new chalcone derivatives produced by benzooxepine triazole methyl ketone

Indexed as

1,2,3-TriazolesADMETlab2.0BenzooxepinesBiological evaluationsChalconesDocking interactions

Identifiers

PMID38590856
PMCPMC10999864
OpenAlexW4393128630

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.